TY - JOUR
T1 - Detecting copy-number variations in whole-exome sequencing data using the exome hidden markov model
T2 - An 'exome-first' approach
AU - Miyatake, Satoko
AU - Koshimizu, Eriko
AU - Fujita, Atsushi
AU - Fukai, Ryoko
AU - Imagawa, Eri
AU - Ohba, Chihiro
AU - Kuki, Ichiro
AU - Nukui, Megumi
AU - Araki, Atsushi
AU - Makita, Yoshio
AU - Ogata, Tsutomu
AU - Nakashima, Mitsuko
AU - Tsurusaki, Yoshinori
AU - Miyake, Noriko
AU - Saitsu, Hirotomo
AU - Matsumoto, Naomichi
N1 - Publisher Copyright:
© 2015 The Japan Society of Human Genetics.
PY - 2015/4/30
Y1 - 2015/4/30
N2 - Whole-exome sequencing (WES) is becoming a standard tool for detecting nucleotide changes, and determining whether WES data can be used for the detection of copy-number variations (CNVs) is of interest. To date, several algorithms have been developed for such analyses, although verification is needed to establish if they fit well for the appropriate purpose, depending on the characteristics of each algorithm. Here, we performed WES CNV analysis using the eXome Hidden Markov Model (XHMM). We validated its performance using 27 rare CNVs previously identified by microarray as positive controls, finding that the detection rate was 59%, or higher (89%) with three or more targets. XHMM can be effectively used, especially for the detection of >200 kb CNVs. XHMM may be useful for deletion breakpoint detection. Next, we applied XHMM to genetically unsolved patients, demonstrating successful identification of pathogenic CNVs: 1.5-1.9-Mb deletions involving NSD1 in patients with unknown overgrowth syndrome leading to the diagnosis of Sotos syndrome, and 6.4-Mb duplication involving MECP2 in affected brothers with late-onset spasm and progressive cerebral/cerebellar atrophy confirming the clinical suspect of MECP2 duplication syndrome. The possibility of an 'exome-first' approach for clinical genetic investigation may be considered to save the cost of multiple investigations.
AB - Whole-exome sequencing (WES) is becoming a standard tool for detecting nucleotide changes, and determining whether WES data can be used for the detection of copy-number variations (CNVs) is of interest. To date, several algorithms have been developed for such analyses, although verification is needed to establish if they fit well for the appropriate purpose, depending on the characteristics of each algorithm. Here, we performed WES CNV analysis using the eXome Hidden Markov Model (XHMM). We validated its performance using 27 rare CNVs previously identified by microarray as positive controls, finding that the detection rate was 59%, or higher (89%) with three or more targets. XHMM can be effectively used, especially for the detection of >200 kb CNVs. XHMM may be useful for deletion breakpoint detection. Next, we applied XHMM to genetically unsolved patients, demonstrating successful identification of pathogenic CNVs: 1.5-1.9-Mb deletions involving NSD1 in patients with unknown overgrowth syndrome leading to the diagnosis of Sotos syndrome, and 6.4-Mb duplication involving MECP2 in affected brothers with late-onset spasm and progressive cerebral/cerebellar atrophy confirming the clinical suspect of MECP2 duplication syndrome. The possibility of an 'exome-first' approach for clinical genetic investigation may be considered to save the cost of multiple investigations.
UR - http://www.scopus.com/inward/record.url?scp=84929089105&partnerID=8YFLogxK
U2 - 10.1038/jhg.2014.124
DO - 10.1038/jhg.2014.124
M3 - Article
C2 - 25608832
AN - SCOPUS:84929089105
SN - 1434-5161
VL - 60
SP - 175
EP - 182
JO - Journal of Human Genetics
JF - Journal of Human Genetics
IS - 4
ER -